1. Home
  2. LU vs CADL Comparison

LU vs CADL Comparison

Compare LU & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lufax Holding Ltd each representing two (2)

LU

Lufax Holding Ltd each representing two (2)

SELL

Current Price

$7.17

Market Cap

715.9M

Sector

Finance

ML Signal

SELL

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$6.06

Market Cap

641.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LU
CADL
Founded
2005
1999
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
715.9M
641.2M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
LU
CADL
Price
$7.17
$6.06
Analyst Decision
Buy
Strong Buy
Analyst Count
4
10
Target Price
★ $23.54
$17.67
AVG Volume (30 Days)
555.1K
★ 1.3M
Earning Date
10-27-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 58.62
EPS
★ N/A
N/A
Revenue
N/A
★ $125,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.80
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.83
$4.35
52 Week High
$9.60
$14.00

Technical Indicators

Market Signals
Indicator
LU
CADL
Relative Strength Index (RSI) 61.15 29.24
Support Level $1.38 $4.62
Resistance Level $9.31 $9.56
Average True Range (ATR) 0.61 0.68
MACD -0.30 -0.16
Stochastic Oscillator 25.31 14.19

Price Performance

Historical Comparison
LU
CADL

About LU Lufax Holding Ltd each representing two (2)

Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: